Navigation Links
AMA Backs Red Cross Blood Service Campaign For More Blood Donors

AMA President, Dr Mukesh Haikerwal, today urged more Australians to donate blood and donate it regularly to meet Australia’s growing demand// for blood.

Dr Haikerwal said the AMA strongly supports the Australian Red Cross Blood Service’s 4 Seasons campaign, which is designed to raise the number of Australian blood donors and increase the number of times these donors give blood each year.

“Blood donors save lives,” Dr Haikerwal said.

“Demand for blood will increase by more than 120 per cent over the next decade, so we need to at least double the blood donation rate if Australia is to have a self-sufficient blood supply.

“Every Australian family will have a family member or friend or acquaintance who will need blood one day, so we must spread the message of the benefits of being a blood donor.

“Donating blood and a little bit of time four times a year brings great rewards, mainly the knowledge that your blood will save the life or enhance the life of another person.

“The AMA will be calling on all its members to sign up to the 4 Seasons campaign, and will promote blood donation at every opportunity.

“We wish the Australian Red Cross Blood Service every success with this campaign – the health of Australia depends upon it,” Dr Haikerwal said.

Source-MA
SRM
'"/>




Page: 1

Related medicine news :

1. AMA Backs Advance Care Planning by Patients
2. Unbelted Backseat Passengers Produce Deadly Results
3. Thailand Backs Off Threat to Break Drug Patents
4. E.U. Panel Backs Novartis Mock-up Pandemic Flu Vaccine
5. U.K. Backs Program To Improve Drug Access in Developing Countries
6. FDA attacks American Red Cross for blood violations
7. Encephalitis Death Toll In U.P. Crosses 200 Mark.
8. Encephalitis Deaths Cross 220 in Uttar Pradesh
9. First Crossover Kidney Transplantation In Germany
10. Blue Cross Signs Up 110,000 Minnesotans For Part D Medicare Plans
11. Red Cross Says Fund Boost and Awareness Are the Main Ingredients to Fight AIDS
Post Your Comments:
*Name:
*Comment:
*Email:


(Date:8/17/2017)... ... August 17, 2017 , ... ... Group, a Florida-based oncology business advisor to oncology practices, announced today the results ... amount of attributable savings from resolving critical clinical issues that would have otherwise ...
(Date:8/16/2017)... ... August 16, 2017 , ... The next Patient Care Academy at Kalamazoo Valley ... who successfully complete the seven-week long Patient Care Academy are eligible to take the ... salary for a CNA in Kalamazoo is $24,428.* , As a CNA, one is ...
(Date:8/16/2017)... ... August 16, 2017 , ... An August 3rd article on Reuters covers ... of a report in JAMA (the Journal of the American Medical Association). The study found ... to achieve BMIs under 30, when compared to patients with lower BMIs. At present, weight ...
(Date:8/16/2017)... (PRWEB) , ... August 16, 2017 , ... Ten outstanding ... Union's Stars in the Classroom and will win a visit by a Houston Texans ... K-12 who are at least five years old can visit texanschecking.com/stars to nominate their ...
(Date:8/16/2017)... ... August 16, 2017 , ... Any Lab Test ... The company ranked #4429 on the newly released, 36th annual Inc. 5000 , ... unique look at the most successful companies within the American economy’s most dynamic segment ...
Breaking Medicine News(10 mins):
(Date:7/26/2017)... -- E.I. Medical Imaging (EIMI) has partnered with Dr. ... the worlds first ultrasound system to be used underwater to ... In preparation for a piece produced by Icon films ... Guttridge approached EIMI with the idea of an underwater ultrasound ... underwater. EIMI produces ...
(Date:7/26/2017)... , July 26, 2017 Sancilio Pharmaceuticals ... of our clinical trial evaluating Altemia TM , an ... (SCA) and Sickle Cell Disease (SCD). The SCOT Trial, ... the efficacy and safety of Altemia TM in ... conducted under US IND 125274. ...
(Date:7/25/2017)... Massachusetts , July 25, 2017 The med-tech ... rare nervous system diseases, has concluded a worldwide license agreement ... drug SOM0226 against transthyretin amyloidosis (ATTR). Before this licensing agreement ... a Phase 2 study conducted in Europe ... the United States ...
Breaking Medicine Technology: